Mycenax Biotech (ROCO:4726) Other Current Payables: NT$149.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4726 Mycenax Biotech Inc ROCO:4726
42 GF Score
Price NT$24.50
GF Value NT$48.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mycenax Biotech Other Current Payables?

Mycenax Biotech ROCO:4726 -2.00% 42 Other Current Payables is NT$149.4 Mil as of Dec. 2025. GuruFocus rates ROCO:4726 with a GF Score™ of 42/100 and a GF Value™ of NT$48.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

Mycenax Biotech's Other Current Payables for the quarter that ended in Dec. 2025 was NT$149.4 Mil.

Mycenax Biotech's quarterly Other Current Payables increased from Jun. 2025 (NT$106.4 Mil) to Sep. 2025 (NT$139.4 Mil) and increased from Sep. 2025 (NT$139.4 Mil) to Dec. 2025 (NT$149.4 Mil).

Mycenax Biotech's annual Other Current Payables declined from Dec. 2023 (NT$361.3 Mil) to Dec. 2024 (NT$177.4 Mil) and declined from Dec. 2024 (NT$177.4 Mil) to Dec. 2025 (NT$149.4 Mil).

Mycenax Biotech Other Current Payables Related Terms

Mycenax Biotech Other Current Payables Historical Data

* Premium members only.

The historical data trend for Mycenax Biotech's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mycenax Biotech Other Current Payables Chart

Mycenax Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.87 195.38 361.32 177.45 149.41

Mycenax Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.45 122.38 106.43 139.39 149.41
ROCO:4726
42GF Score
Mycenax Biotech Inc ROCO:4726
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mycenax Biotech Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$149.4 Mil mean?
Mycenax Biotech (ROCO:4726) has a Other Current Payables of NT$149.4 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Mycenax Biotech and its competitors.
Is Mycenax Biotech's Other Current Payables too high?
Mycenax Biotech's current Other Current Payables is NT$149.4 Mil. Overall, Mycenax Biotech has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Other Current Payables compare to VRTX and REGN?
Mycenax Biotech's Other Current Payables of NT$149.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Mycenax Biotech and its competitors. Mycenax Biotech's current Other Current Payables is NT$149.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.37, compared to a current price of NT$24.50 — trading 49.3% below its estimated fair value. The current Other Current Payables is NT$149.4 Mil. Mycenax Biotech's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Other Current Payables is NT$149.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?

Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued. The current stock price of NT$24.50 is trading 49.3% below its estimated GF Value™ of NT$48.37. GuruFocus considers Mycenax Biotech to be Possible Value Trap.

Key valuation signals for ROCO:4726:

  • Other Current Payables: NT$149.4 Mil
  • GF Value™: NT$48.37 vs. price of NT$24.50 (49.3% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mycenax Biotech Business Description

Address No. 66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
42GF Score

Get the complete analysis for ROCO:4726

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.50
Price
NT$48.37
GF Value